Novartis announces new CEO
Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018.
List view / Grid view
News
Beta blockers have positive effect in pulmonary arterial hypertension
A team of researchers have found that a common heart disease medication may help treat lung disease...
Pharma businesses failing to report data breaches
The real extent of the pharma sector’s problem with data breaches has been revealed...
FDA approves CAR T cell therapy for children with leukaemia
The FDA has approved CAR T cell therapy for treatment of children with acute lymphoblastic leukemia...
Z-endoxifen shows promise for breast cancer
Z-endoxifen, a potent derivative of the drug tamoxifen, could itself be a new treatment for the most common form of breast cancer...
MRI can measure kidney scarring and predict future kidney function
Researchers have made what are believed to be two world first discoveries: an MRI that can measure kidney damage and predict future kidney function...
Metformin may help in Parkinson’s disease
Researchers have found that a diabetes drug may help in certain types of Parkinson’s disease...
Immunotherapy combination effective at killing cancer cells
Researchers have recently discovered an immunotherapy that uses existing cancer drugs in a whole new way...
FDA approves new antibacterial drug
The FDA has approved Vabomere for adults with complicated urinary tract infections...
Economic incentives and research quality – a letter to the editor
Prof Giovanni Di Guardo, from the University of Teramo, suggests that economic incentives for publishing in high-profile Journals do not appear to hold the key to success
Anacetrapib reduces risk of serious cardiovascular events
An international clinical trial has assessed the efficacy and safety of adding anacetrapib versus placebo atorvastatin in patients with vascular diseases...
Combination of conventional drugs enhances tumour cell death
Brazilian researchers have investigated whether cisplatin and 5-FU would interfere with the protein pRB...
Sildenafil should be avoided in valvular disease
The SIOVAC trial2 has tested the potential of sildenafil to improve long-term outcomes of patients with residual pulmonary hypertension...
Dual antithrombotic therapy cuts bleeding risk
Researchers have found that using just two anti-clotting medicines for atrial fibrillation is safer than using the current standard treatments...
Next-generation drug testing on chips
Researchers in Japan have designed a small 'body-on-a-chip' device that can test the side effects of drugs on human cells...
